TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05280938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAAP
Description: Women randomized to the MAAP intervention will complete an 8 week (2hr/wk) hybrid adapted Kabat-Zinn's MBSR.(Kabat-Zinn, 1990) MAAP intervention includes activities related to spirituality, self-empowerment, interdependence, and story-telling, which are salient to AAW.(Watson-Singleton et al., 2019) Women will receive practice links and a program work book (5th grade level) containing objectives and weekly MAAP activities/. Individual weekly home practice is expected. Type and minutes of home practice will be recorded in weekly logs. Program attendance, type, amount of practice, and changes in mindfulness (Five Facet Mindfulness Questionnaire) will be included in data analysis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program
Description: The 8-week Educational Program will be matched in duration, frequency, delivery method, and data collection to the MAAP intervention. Like MAAP, it will be delivered using a hybrid format (virtual Zoom and in person visits).~Sessions will be given in groups by an expert perinatal clinician/educator for all cohorts. Content will be set and delivered consistently across cohorts. Sessions will be audiotaped and rated for achievement of objectives and consistency of delivery. Deviations will be promptly addressed. Subject receipt will be monitored by attendance. Sessions will not include content on stress reduction (yoga, meditation, etc.). Classes will be given in the same setting as the MAAP intervention, at the same time but on a different evening, to avoid crossover (diffusion) of effects.
Study: NCT06525831

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MR-elastography exam
Description: Imaging acquisition

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound exam
Description: Imaging acquisition
Study: NCT05306028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin or insulin treatment
Description: 1. For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose \> 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.~2. For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose.
Study: NCT05306912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
Study: NCT06775925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral robot-assisted therapy (RT)
Description: RT will be performed as an add-on therapy to the clinical routine therapy scheme for 3 x 30 minutes per week for 6 weeks. RT is applied using the ArmeoSpring, an exoskeleton that provides adjustable antigravity weight support for the arm through a system of springs (no actuators).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral conventional occupational therapy (OT)
Description: The OT is applied as add-on therapy for 3 x 30 minutes per week for 6 weeks. OT comprises strengthening exercises (concentric and eccentric) with and without resistance, grasping exercises, fine motor training, peg games, and activity-based tasks which are unilaterally doable.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral conventional occupational therapy (OT)
Description: The OT is applied as add-on therapy for 3 x 30 minutes per week for 6 weeks. OT comprises strengthening exercises (concentric and eccentric) with and without resistance, grasping exercises, fine motor training, peg games, and activity-based tasks which are unilaterally doable.
Study: NCT06775613

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Long-read sequencing
Description: The technology performed belongs to third-generation sequencing strategies and is capable of analysing very long DNA and RNA fragments.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Long-read sequencing
Description: The technology performed belongs to third-generation sequencing strategies and is capable of analysing very long DNA and RNA fragments.
Study: NCT06776835

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of relative quantitative of small non-coding RNAs
Description: Each participant was enrolled to assess the of relative quantitative of small non-coding RNAs

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of relative quantitative of small non-coding RNAs
Description: Each participant was enrolled to assess the of relative quantitative of small non-coding RNAs
Study: NCT06775964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adMSC
Description: IV-infusion of autologous, adipose-derived, Mesenchymal Stem Cells (adMSCs), of approximately 2x10(8) adMSCs in 250mL saline.
Study: NCT06775275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebellizumab
Description: adebrelimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebellizumab
Description: adebrelimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.
Study: NCT06776354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GPT-based training
Description: GPT-based training whether could improve the ability of students to develop effective hypertension management plans

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional training
Description: traditional teaching methods
Study: NCT06776731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula during endurance training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room Air (placebo)
Description: Room air (5l/min) will be applied with an oxygen concentrator via nasal cannula during endurance training.
Study: NCT04697355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: naringenin and beta carotene
Description: Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
Study: NCT06336707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin / carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin / carboplatin
Description: Intravenous infusion
Study: NCT06776757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
Description: Sintilimab (100mg,150mg, 200mg; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
Description: Sintilimab (Based on Phase 1b recommended dose; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
Study: NCT06776523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus
Description: Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy involves handouts and homework reminders.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Problem Management Plus
Description: Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy involves handouts and homework reminders.
Study: NCT06776146

Intervention type: DIAGNOSTIC_TEST
Intervention: proteomic profiling
Description: proteomic profiling
Study: NCT06379997

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen, Hyaluronic Acid, Vitamin C, and Manganese
Description: The Group 1 (G1) will begin taking a dietary supplement the day after enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular infiltration
Description: Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
Study: NCT05743829

Intervention type: PROCEDURE
Intervention: Tissue excision as part of routine clinical care
Description: Tissue excision

Intervention type: PROCEDURE
Intervention: Tissue excision as part of routine clinical care
Description: Tissue excision
Study: NCT05122182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan Cilexetil
Description: Angiotensin Receptor Blocker (ARB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: Angiotensin Receptor Blocker (ARB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repagermanium
Description: C-C chemokine receptor type 2 (CCR2) antagonist
Study: NCT06296797

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm: Existing educational website
Description: Information about tubal sterilization currently provided on the Planned Parenthood website
Study: NCT06776146

Intervention type: DIAGNOSTIC_TEST
Intervention: proteomic profiling
Description: proteomic profiling

Intervention type: DIAGNOSTIC_TEST
Intervention: proteomic profiling
Description: proteomic profiling
Study: NCT06296797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advancing Access Website
Description: A website comparing tubal sterilization to long-acting reversible contraceptives informed by recent patient centered outcomes research.
Study: NCT05122182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan Placebo
Description: Angiotensin Receptor Blocker (ARB) placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Repagermanium Placebo
Description: C-C chemokine receptor type 2 (CCR2) antagonist placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Repagermanium Placebo
Description: C-C chemokine receptor type 2 (CCR2) antagonist placebo
Study: NCT06776081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss without pharmacotherapy
Description: Adults with obesity participating in the 12-week hypocaloric diet-induced weight loss intervention will be individually counseled by the Clinical and Translational Research Center (CTRC) bionutritionist to consume a hypocaloric diet consistent with current dietary recommendations for weight loss until a 6-10% weight loss is achieved.
Study: NCT06776250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a BiTE molecule designed to direct T effector cells toward DLL3-expressing cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a BiTE molecule designed to direct T effector cells toward DLL3-expressing cells.
Study: NCT06775418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound erector spinae plane block
Description: Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group U (15 patients):will receive bilateral US guided single shot ESPB, 30 ml of bupivacaine 0.25% on each side after induction of anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dexamedotomidine infusion after induction of anesthesia
Description: Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group D (15 patients):will receive the study drug infusion (Dexmedetomidine) after induction of anesthesia.
Study: NCT06777342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy intervention
Description: The cognitive behavioral intervention provides sleep-related education 7-14 days before surgery. The educational content should include the following aspects: 1) Establish a consistent bedtime and wake-up time, recommending a sleep schedule from 22:00 to 07:00, and avoid prolonged daytime naps; 2) Optimize the sleep environment by ensuring a quiet setting, turning off lights, and refraining from using mobile phones, computers, and other electronic devices 30 minutes before bedtime; 3) Manage diet by avoiding caffeinated foods such as chocolate, tea, and cola; 4) Engage in appropriate daytime activities as permitted by the patient's condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy intervention
Description: The cognitive behavioral intervention provides sleep-related education 7-14 days before surgery. The educational content should include the following aspects: 1) Establish a consistent bedtime and wake-up time, recommending a sleep schedule from 22:00 to 07:00, and avoid prolonged daytime naps; 2) Optimize the sleep environment by ensuring a quiet setting, turning off lights, and refraining from using mobile phones, computers, and other electronic devices 30 minutes before bedtime; 3) Manage diet by avoiding caffeinated foods such as chocolate, tea, and cola; 4) Engage in appropriate daytime activities as permitted by the patient's condition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin intervention
Description: Patients in the melatonin intervention group are required to take an oral melatonin of 5 mg at 30-60 minutes before sleep (administered at 21:00) nightly for 7 to 14 days before surgery. The melatonin was provided by Kangenbei Pharmaceutical Co., LTD. (Hangzhou, Zhejiang, China).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo intervention
Description: Patients in the placebo group need to take oral placebos of 5 mg at 30-60 minutes (administered at 21:00) before sleep, nightly, for 7 to 14 days before surgery. The placebo is provided by Guangzhou Boji Biomedical Science Park Co., LTD. (Guangzhou, Guangdong, China).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Patients in the placebo group need to take oral placebos of 5 mg at 30-60 minutes (administered at 21:00) before sleep, nightly, for 7 to 14 days before surgery. The placebo is provided by Guangzhou Boji Biomedical Science Park Co., LTD. (Guangzhou, Guangdong, China).
Study: NCT06776042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal brushing of the olfactory cleft
Description: Nasal brushing of the olfactory cleft

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell testing
Description: Smell testing using the Sniffin' Sticks Test
Study: NCT06776406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Pursuit Robotic Platform
Description: The Freedom Pursuit Robotic Platform is a robotic head holder device that uses data from the AlignRT system (3D surface imager) to make small movements of a patient's head to stabilize it during radiation therapy.
Study: NCT05301842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous)
Study: NCT05497011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCSO Impulse System
Description: After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
Study: NCT05042999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go Virtual Reality Goggles
Description: Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments. Non pharmacological technique to reduce pain and anxiety during a procedure.
Study: NCT06396117

Intervention type: OTHER
Intervention: mTESE (microscopic testicular sperm extraction)
Description: Microdissection Testicular Sperm Extraction (mTESE) is a surgical procedure used to retrieve sperm from the testicles of men with non-obstructive azoospermia (NOA). It involves:~1. Testicular biopsy: Removing a small sample of testicular tissue.~2. Microscopic examination: Examining the tissue under a microscope to identify areas with sperm production.~3. Sperm extraction: Dissecting out individual sperm cells from the testicular tissue.~This technique allows for:~* More accurate identification of sperm-containing areas~* Lower risk of damage to surrounding testicular tissue~* Potential for higher sperm retrieval rates compared to conventional method

Intervention type: OTHER
Intervention: mTESE (microscopic testicular sperm extraction)
Description: Microdissection Testicular Sperm Extraction (mTESE) is a surgical procedure used to retrieve sperm from the testicles of men with non-obstructive azoospermia (NOA). It involves:~1. Testicular biopsy: Removing a small sample of testicular tissue.~2. Microscopic examination: Examining the tissue under a microscope to identify areas with sperm production.~3. Sperm extraction: Dissecting out individual sperm cells from the testicular tissue.~This technique allows for:~* More accurate identification of sperm-containing areas~* Lower risk of damage to surrounding testicular tissue~* Potential for higher sperm retrieval rates compared to conventional method
Study: NCT05572697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive-behavioral therapy for insomnia (dCBT-I)
Description: 6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
Study: NCT05425966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS-R-FUERTE
Description: The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
Study: NCT05301842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE (chemo and embolic agent injection into the hepatic artery)
Study: NCT04402515

Intervention type: DRUG
Intervention: TIO/OLO
Description: Tiotropium/Olodaterol

Intervention type: DRUG
Intervention: ICS
Description: inhaled cortocosteroids
Study: NCT05269628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD)
Description: Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrocannabinol (THC)
Description: The drug dose will be 2.5 mg b.i.d. during the first 7 days of active treatment, and 5 mg b.i.d. for the following treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrocannabinol (THC)
Description: The drug dose will be 2.5 mg b.i.d. during the first 7 days of active treatment, and 5 mg b.i.d. for the following treatment.
Study: NCT05301842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE (chemo and embolic agent injection into the hepatic artery)
Study: NCT05269628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CBD
Description: Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
Study: NCT05301842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE (chemo and embolic agent injection into the hepatic artery)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib (oral)